Jazz Pharmaceuticals plc (JAZZ)
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
Examine Jazz's (JAZZ) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
Jazz Pharmaceuticals JAZZ has reached a milestone that most conventional cannabis players are yet to achieve — generating sustained, billion-dollar revenues from a cannabis product.
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings
Evaluate the expected performance of Jazz (JAZZ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock?
Investors need to pay close attention to Jazz Pharmaceuticals stock based on the movements in the options market lately.
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
